Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    DEAR TAKEDA FRIENDS, WE IN THE AMGEN ONCOLOGY BUSINESS UNIT HATE AND LOATH ONYX REPS. PLEASE DESTROY THEM BY TALKING ABOUT THEIR HORRIBLE AES AND CARDIAC TOXICITY. WE WANT THEM TO FAIL AND FALL FLAT ON THEIR FACE!

    - AMGEN ONCOLOGY


    Amgen Inc's Kyprolis helped patients with relapsed multiple myeloma live twice as long before their blood cancer worsened compared to a regimen containing rival drug Velcade, according to an interim analysis announced by the company on Sunday.

    Kyprolis, the centerpiece of Amgen's nearly $10 billion acquisition of Onyx Pharmaceuticals in 2013, had sales last year of $331 million. Velcade, sold by Takeda Pharmaceutical Co and Johnson & Johnson, had 2014 sales of nearly $3 billion.

    The interim look showed that patients with relapsed multiple myeloma treated with Kyprolis and chemotherapy drug dexamethasone lived for a median of 18.7 months before their disease worsened, compared with 9.4 months for patients treated with Velcade and dexamethasone.

    Amgen said the study has yet to show a difference in overall survival between the two groups, but said it did demonstrate superiority for Kyprolis in secondary goals of higher overall response rate and lower incidence of nerve pain.

    Sean Harper, Amgen's head of research and development, said the study will continue until a full analysis of overall survival can be determined.

    "This was the bet we made when we acquired Onyx," he said. "To be able to demonstrate something compelling enough with respect to the difference between Kyprolis and Velcade," which will lose U.S. patent protection in 2017.

    Rates of cardiac failure and kidney failure for Kyprolis were comparable to those observed in a prior study in a similar patient population, but were higher than for patients treated with Velcade. There was also an increase in the incidence of hypertension and shortness of breath in the Kyprolis group compared to Velcade.

    The U.S. Food and Drug Administration, in 2012, granted Kyprolis accelerated approval for use in multiple myeloma, the second most common form of blood cancer, after prior therapies stopped working.

    Amgen filed earlier this year for FDA approval of Kyprolis as a second-line myeloma treatment based on positive results from a study comparing the drug to another older treatment, Celgene Corp's Revlimid.

    Results from a head-to-head trial comparing Kyprolis to Velcade in newly diagnosed multiple myeloma patients are likely to come in 2016, Harper said.

    Amgen said its latest trial results will be submitted for presentation at the American Society of Clinical Oncology's 2015 meeting.

    "Demonstrating superiority over Velcade in this head-to-head trial supports our goal of ensuring continued improvement of patient outcomes and potentially establishing Kyprolis as the backbone of therapy for patients with multiple myeloma," Pablo Cagnoni, president of Amgen's Onyx unit, said in a statement.
     

  2. Anonymous

    Anonymous Guest

    Onyx reps are losers.

    Velcade is better. Their AE event profile will limit usage.

    "Rates of cardiac failure and kidney failure for Kyprolis were comparable to those observed in a prior study in a similar patient population, but were higher than for patients treated with Velcade. There was also an increase in the incidence of hypertension and shortness of breath in the Kyprolis group compared to Velcade."
     
  3. Anonymous

    Anonymous Guest

    U mad bro? Freakin double your asses up homies! Discontinuation rates the same, cardiac? Whatever, this is Cancer? Velcade is done, better get that dog of an oral to market quick, we will double that up too! See you losers at meetings with hate in your eyes while we are smiling all the way to the bank! Nice run brah!
     
  4. Anonymous

    Anonymous Guest

    Last time I looked, Kyprolis is the only drug without any black box warnings or contraindications. This is used to treat cancer, if there was a signal, you would see a black box dumbass. These oncologists are smart and heard they are all switching to Kyprolis immediately. This is Cancer, life and death, and we just doubled your asses up! Mine as well give them dex, same response losers!
     
  5. Anonymous

    Anonymous Guest

  6. Anonymous

    Anonymous Guest

    typical of Amgen. Wait till they promote this drug too. Offices will begin to shut down even more.
     
  7. Anonymous

    Anonymous Guest

  8. Anonymous

    Anonymous Guest

    Amgen = Supportive Care, not Oncology
     
  9. Anonymous

    Anonymous Guest

    Takeda = Repeated Phase 3 failures, not a development company
     
  10. anonymous

    anonymous Guest

     
  11. anonymous

    anonymous Guest


    Really? you may need to read your PI and our PI's. Fucking idiot!